Australia's most trusted
source of pharma news
Monday, 23 December 2024
Posted 3 December 2021 PM
Speculation is rife that CSL is in talks to buy Swiss pharma Vifor, in a deal worth more than $10 billion.
CSL is already part way through due diligence, and "has a big team working on the case", according to the Australian Financial Review (AFR).Vifor's shares jumped over 20 per cent to 125 Swiss francs on the reports.
Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.
Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.